CoChat
Sign Up
Cited by 55Schizophrenia research and treatmentTreatment of Major DepressionNeurotransmitter Receptor Influence on Behavior

A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis

Open access
Kimura, Hiroshi, Kanahara, Nobuhisa, Komatsu, Naoya, Ishige, Minoru, Muneoka, Katsumasa, Yoshimura, Masayuki, Yamanaka, Hiroshi, Suzuki, Tomotaka +12 more·2014·Schizophrenia Research
DOI 10.1016/j.schres.2014.02.022
Open this paper in CoChat — free account

Abstract

OBJECTIVE: Dopamine supersensitivity psychosis (DSP) is considered to be one cause of treatment-resistant schizophrenia (TRS). The authors investigated the efficacy of risperidone long-acting injections (RLAI) in patients with TRS and DSP. METHOD: This is a multicenter, prospective, 12-month follow-up, observational study that included unstable and severe TRS patients with and without DSP. 115 patients with TRS were recruited and divided into two groups according to the presence or absence of DSP which was judged on the basis of the clinical courses and neurological examinations. RLAI was administered adjunctively once every 2weeks along with oral antipsychotics. We observed changes in scores for the Brief Psychiatric Rating Scales (BPRS), Clinical Global Impression-Severity of Illness (CGI-S), Global Assessment of Functioning Scale (GAF), and Extrapyramidal Symptom Rating Scale (ESRS) during the study. Of the assessed 94 patients, 61 and 33 were categorized into the DSP and NonDSP groups, respectively. RESULTS: While baseline BPRS total scores, CGI-S scores and GAF scores did not differ, the ESRS score was significantly higher in the DSP group compared with the NonDSP group. Treatment significantly reduced BPRS total scores and CGI-S scores, and increased GAF scores in both groups, but the magnitudes of change were significantly greater in the DSP group relative to the NonDSP group. ESRS scores were also reduced in the DSP group. Responder rates (≥20% reduction in BPRS total score) were 62.3% in the DSP group and 21.2% in the NonDSP group. CONCLUSIONS: It is suggested that DSP contributes to the etiology of TRS. Atypical antipsychotic drugs in long-acting forms, such as RLAI, can provide beneficial effects for patients with DSP. CLINICAL TRIALS REGISTRATION: UMIN (UMIN000008487).

Integrity signals

Registry

Crossref · 10.1016/j.schres.2014.02.022

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Kimura, H., Kanahara, N., Komatsu, N., Ishige, M., Muneoka, K., Yoshimura, M., Yamanaka, H., Suzuki, T., Komatsu, H., Sasaki, T., Hashimoto, T., Hasegawa, T., Shiina, A., Ishikawa, M., Sekine, Y., Shiraishi, T., Watanabe, H., Shimizu, E., Hashimoto, K., & Iyo, M.
Affiliations
  • Chiba University (JP)
  • Chiba Hospital (JP)
  • Sodegaura Satsukidai Hospital (JP)
  • Chiba University Hospital (JP)
Corresponding author
Kanahara, Nobuhisa
ORCID
Venue
Schizophrenia Research
Publisher
Elsevier BV
Published
2014-05
Volume
155
Issue
1-3
Pages
52-58
ISSN
0920-9964 (ISSN-L)
DOI
10.1016/j.schres.2014.02.022
OpenAlex
W2008349757
Cited by
55
References
45
Citations by year
2026: 4 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 4 · 2021: 7 · 2020: 5 · 2019: 2 · 2018: 5 · 2017: 7 · 2016: 6 · 2015: 8 · 2014: 1 · 2013: 1
FWCI
5.59
Type
journal article
Language
en
Open access
Licence
Locations
  • Schizophrenia Research (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Funders
Ministry of Health, Labour and Welfare
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
long-acting injectable risperidone, treatment-resistant schizophrenia
MeSH terms
Administration, Oral, Adolescent, Adult, Aged, Dopamine, Drug Administration Routes, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Psychiatric Status Rating Scales, Psychotic Disorders, Schizophrenia, Antipsychotic Agents, Drug Delivery Systems, Treatment Outcome, Risperidone, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review